Table 2.
Descriptive Characteristics of Drug Regimen Pathways by Drug Regimen Line
| Characteristic | Drug Group | |||||
|---|---|---|---|---|---|---|
| No. (%) of Patients in Drug Group (Relative to Remaining Patients) |
Median Time to Treatment, Days (Follow-up Start to Treatment) |
|||||
| First-Line | Second-Line | Third-Line | First-Line | Second-Line | Third-Line | |
| Total patients continuing to line (cumulative % continuing to line) | ||||||
| Total patients remaining | 51 066 (100) | 17 707 (34.7) | 6259 (12.3) | … | … | … |
| No. of patients with each drug regimen (% with each drug regimen of those remaining) | ||||||
| CS | 11 947 (23.4) | 4159 (23.6) | 683 (11.0) | 0 | 5 | 5 |
| RDV | 2271 (4.4) | 17 (0.1) | 18 (0.3) | 0 | 3 | 10 |
| CS + RDV | 12 832 (25.1) | 3894 (22.1) | 46 (0.7) | 0 | 1 | 3 |
| IL-6i + CS | 422 (0.8) | 922 (5.2) | 1120 (18.1) | 1 | 5 | 5 |
| IL-6i + CS + RDV | 632 (1.2) | 1098 (6.2) | 218 (3.5) | 0 | 1 | 3 |
| Any IL-6i combination therapy (IL-6i + CS and IL-6i + CS + RDV) |
1054 (2.1) | 2020 (11.4) | 1338 (21.4) | … | … | … |
| JAKi + CS | 403 (0.8) | 818 (4.6) | 911 (14.7) | 1 | 5 | 5 |
| JAKi + CS + RDV | 761 (1.5) | 1146 (6.5) | 187 (3.0) | 0 | 1 | 3 |
| Any JAKi combination therapy (JAKi + CS and JAKi + CS + RDV) |
1164 (2.3) | 1964 (11.1) | 1098 (17.5) | … | … | … |
| No treatmenta | 21 603 (42.3) | 5408 (30.7) | 2814 (45.4) | 0 | 5 | 7 |
Abbreviations: CS, corticosteroids; IL-6i, interleukin-6 inhibitor; JAKi, Janus kinase inhibitor; RDV, remdesivir.
a
No treatment in the first-line column indicates patients who never received treatment during their hospital time and therefore were not assigned a first-line treatment.